NCT03559673No Longer AvailableNot Applicable
Compassionate Use Program With Lacosamide in Patients With Partial-onset or Generalized Tonic-clonic Seizures ≥16 Years of Age Coming From the SP0994 Study
UCB Biopharma S.P.R.L.0 sitesStarted: June 18, 2018Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- No Longer Available
- Sponsor
Study Overview
Brief Summary
The objective of this Compassionate Use Program (CUP) is to provide continued access to Lacosamide (LCM) for monotherapy use for patients who were receiving LCM in SP0993 and SP0994 at the time of study unblinding and close of SP0994, and who benefited from the treatment per investigator assessment.
Study Design
- Study Type
- Expanded Access
Eligibility Criteria
- Ages
- 16 Years to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patient has completed the Termination Visit of SP0994 and has been treated with Lacosamide (LCM) monotherapy
- •Patient is expected to benefit from participation in the Compassionate Use Program (CUP) with LCM monotherapy, in the opinion of the treating physician
- •Patient is willing and able to comply with all program requirements
- •Patient is informed of the details of this CUP, is given ample time and opportunity to ask questions and consider his/her participation in this CUP, and the patient or the legally authorized representative (LAR) has provided verbal consent to participate, and, if applicable to local regulations, has given written informed consent
Exclusion Criteria
- •Patient is receiving any investigational drugs or using any experimental devices in addition to LCM
- •For countries where LCM is reimbursed: Patient requires another anti-epileptic drug (AED) for the treatment of seizures For countries where LCM is not reimbursed (or conditionally reimbursed: Belgium, Australia e.g.): Patient requires another AED for the treatment of seizures and qualifies for commercial LCM (and LCM is being reimbursed)
- •Patient experienced emergence of a seizure type other than partial-onset or generalized tonic-clonic seizures, or occurrence of status epilepticus
- •Patient developed second- or third-degree atrioventricular (AV) block or another clinically relevant change in medical condition (or electrocardiogram (ECG) or laboratory parameter)
- •Patient having liver function test (LFT) results of transaminases (aspartate aminotransferase [AST] and/or alanine aminotransferase [ALT]) ≥3×ULN to <5×upper limit of normal (ULN)
- •Patient has actual suicidal ideation or behavior
- •Patient is experiencing an ongoing serious adverse event (SAE) and there is no expected benefit for him/her to continue on LCM treatment
- •Female patient who is pregnant or nursing, and/or a woman of childbearing potential who is not surgically sterile, 2 year postmenopausal or does not practice one highly effective method of contraception (according to ICH guidance defined as those that result in a failure rate of less than 1 % per year when used consistently and correctly), unless sexually abstinent, for the duration of the study
- •Patient was treated with carbamazepine controlled release (CBZ-CR) in SP0994
Investigators
Similar Trials
Available
Not Applicable
Linerixibat Compassionate Use for Cholestatic Pruritus Adult Patients With Primary Biliary Cholangitis (PBC)PruritusNCT05448170GlaxoSmithKline
No Longer Available
Not Applicable
CUP Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD)Crohn's DiseaseNCT03559660UCB Biopharma SRL
Available
Not Applicable
A Compassionate Use Program to Provide Access to Sodium ThiosulfateCisplatin-Induced Hearing Loss in Children Who Had Standard-risk HepatoblastomaNCT04132882TRPHARM
Approved For Marketing
Not Applicable
Compassionate Use Program for Olipudase Alfa Enzyme Replacement Therapy for Patients With Chronic Acid Sphingomyelinase Deficiency (ASMD)Sphingomyelin LipidosisNCT04877132Sanofi
No Longer Available
Not Applicable
Compassionate Use Program With Brivaracetam for the Treatment of Patients With EpilepsyEpilepsyNCT03532516UCB Biopharma SRL